Alpha Tau Medical to Present at the Sidoti March Virtual Small-Cap Conference

JERUSALEM, March 16, 2026 — Alpha Tau Medical Ltd., an innovative oncology therapeutics company focused on the development of targeted alpha-radiation therapies for the treatment of solid tumors, has announced that it will participate in the Sidoti March Virtual Small-Cap Conference. The conference is scheduled to take place virtually on March 18–19, 2026, bringing together emerging companies and institutional investors for discussions on growth strategies, technological innovations, and investment opportunities.

The participation of Alpha Tau in this event reflects the company’s commitment to maintaining transparent communication with the investment community while showcasing the progress of its proprietary cancer treatment platform, Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy). During the conference, company executives will provide a corporate overview, share updates on clinical development programs, and highlight upcoming milestones that may drive value for shareholders.

Sidoti March Virtual Small-Cap Conference Overview

The Sidoti Virtual Small-Cap Conference is a prominent investment event focused on small and micro-cap publicly traded companies. Hosted by Sidoti & Company, the conference offers a platform for emerging businesses to present their strategy, financial outlook, and technological innovations directly to institutional investors, analysts, and industry professionals.

Taking place over two days, the March conference features a wide range of companies from sectors including biotechnology, healthcare, technology, industrials, and financial services. Presenting companies typically deliver formal presentations and participate in virtual one-on-one meetings with investors, allowing for deeper engagement and discussion about corporate developments.

Sidoti’s conference series has developed a reputation as a key event in the small-cap investment ecosystem. Through its network of institutional relationships across North America, the conference facilitates meaningful dialogue between investors and corporate leaders, helping companies expand visibility within the capital markets.

For Alpha Tau, this conference provides a valuable opportunity to communicate recent progress in its oncology pipeline and discuss the future potential of its innovative cancer therapy platform.

Alpha Tau’s Planned Presentation and Investor Engagement

During the Sidoti conference, Alpha Tau executives will present a comprehensive overview of the company’s operations and strategic vision. The presentation will include key updates on clinical trials, regulatory progress, and research developments related to the company’s flagship technology.

Investors attending the event will gain insights into:

Corporate Strategy and Business Model

The company plans to outline its long-term strategy for expanding the clinical and commercial potential of Alpha DaRT. This includes advancing ongoing clinical trials, strengthening partnerships with medical institutions, and exploring opportunities to broaden the application of the technology across multiple tumor types.

Clinical Development Pipeline

Alpha Tau continues to advance a series of clinical trials across several types of solid tumors. The conference presentation will highlight key milestones achieved in these trials as well as anticipated developments expected throughout the year.

Investor Meetings and Networking Opportunities

In addition to the formal presentation, Alpha Tau’s leadership team will conduct one-on-one virtual meetings with investors. These sessions allow institutional investors and analysts to ask questions about the company’s research, financial performance, and long-term growth strategy.

Such personalized discussions often provide investors with deeper insight into the company’s outlook, helping them better evaluate the potential of Alpha Tau’s technology and market opportunities.

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company focused on the research, development, and potential commercialization of targeted alpha-radiation therapies for solid tumors.

The company was founded in Israel and has built its scientific foundation on groundbreaking research conducted at Tel Aviv University. The technology underlying Alpha Tau’s therapeutic platform was developed by leading researchers specializing in radiation oncology and cancer biology.

Since its inception, Alpha Tau has aimed to revolutionize cancer treatment by providing highly potent localized radiation therapy capable of destroying tumors while minimizing damage to surrounding healthy tissue.

Today, the company continues to expand its global presence through clinical trials, regulatory collaborations, and strategic partnerships with hospitals, research institutions, and biotechnology organizations.

Understanding Alpha DaRT®: A Breakthrough in Cancer Therapy

What is Alpha DaRT?

Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) is a novel cancer treatment technology designed to deliver highly potent alpha radiation directly inside solid tumors.

The therapy works through the insertion of tiny sources impregnated with the radioactive isotope radium-224 into tumor tissue. As the radium decays, it releases short-lived radioactive daughter atoms that emit high-energy alpha particles.

These alpha particles travel only short distances but carry extremely high energy, allowing them to destroy cancer cells effectively while minimizing damage to nearby healthy tissue.

How Alpha DaRT Targets Tumors

The Alpha DaRT approach is designed to overcome several limitations of traditional radiation therapy.

Key advantages include:

• High-energy tumor destruction through alpha particle emission.
• Localized radiation delivery directly inside the tumor.
• Limited impact on surrounding tissues due to the short travel distance of alpha particles.
• Potential to treat tumors resistant to conventional therapies.

This innovative mechanism offers the potential to treat various solid tumors that are difficult to address with surgery, chemotherapy, or external beam radiation.

Clinical Development and Research Progress

Alpha Tau has launched multiple clinical trials investigating the effectiveness of Alpha DaRT across different cancer indications. These trials are designed to evaluate safety, treatment efficacy, and the potential for broader clinical applications.

The company continues to work closely with regulatory authorities and medical institutions worldwide as it advances the therapy toward commercialization.

Recent Milestones and Regulatory Progress

Alpha Tau has achieved several significant milestones in recent months that highlight the growing recognition of its technology within the global oncology community.

Among the most notable developments is the company’s success in securing regulatory approvals and advancing clinical programs in multiple regions.

For example, Alpha Tau recently obtained marketing approval in Japan for the use of Alpha DaRT in certain head and neck cancers, marking a key step toward international expansion.

Such regulatory achievements reinforce confidence in the safety and effectiveness of the technology and support the company’s efforts to bring its treatment platform to patients worldwide.

Investor Interest and Market Performance

The investment community has shown increasing interest in Alpha Tau’s progress as the company continues to reach new milestones.

Recent analyst reports and market activity suggest that investors are closely monitoring developments related to the company’s clinical pipeline and regulatory achievements.

Shares of Alpha Tau Medical trade on the NASDAQ under the ticker symbol DRTS. The stock has experienced notable fluctuations as investors respond to clinical trial updates, regulatory decisions, and broader biotechnology market trends.

Industry observers note that companies developing breakthrough cancer therapies often attract significant attention from both institutional and retail investors due to the enormous global demand for effective oncology treatments.

The Role of Investor Conferences in Biotech Growth

Investor conferences such as the Sidoti Small-Cap Conference play a crucial role in helping biotechnology companies connect with the investment community.

These events provide a structured platform where corporate leaders can present their vision, discuss scientific breakthroughs, and share financial strategies with investors.

For emerging biotech firms like Alpha Tau, conference participation can help:

• Increase visibility among institutional investors
• Strengthen relationships with analysts and research firms
• Communicate progress in clinical trials and regulatory approvals
• Support future fundraising and strategic partnerships

As the biotechnology industry continues to evolve rapidly, maintaining open communication with investors is essential for companies pursuing cutting-edge medical innovations.

Future Outlook for Alpha Tau

Looking ahead, Alpha Tau aims to continue expanding the clinical applications of its Alpha DaRT technology while advancing toward broader commercialization.

The company’s strategic priorities include:

• Expanding clinical trials across additional tumor types
• Advancing regulatory approvals in major global markets
• Building partnerships with leading cancer treatment centers
• Exploring new technological enhancements to the Alpha DaRT platform

If ongoing clinical trials continue to demonstrate positive outcomes, Alpha Tau’s technology could potentially represent a major breakthrough in the treatment of solid tumors.

The company believes that targeted alpha radiation therapy may play an increasingly important role in the future of oncology treatment.

Conclusion

Alpha Tau Medical’s participation in the Sidoti March Virtual Small-Cap Conference highlights the company’s ongoing commitment to innovation, transparency, and investor engagement.

By presenting its latest scientific and corporate developments to the investment community, Alpha Tau aims to strengthen awareness of its groundbreaking cancer treatment technology and build support for its long-term growth strategy.

As research and clinical trials continue to advance, the company’s Alpha DaRT therapy may offer new hope for patients battling difficult-to-treat solid tumors while also creating meaningful opportunities for investors interested in the rapidly evolving biotechnology sector.

#AlphaTau #CancerTherapy #BiotechNews #SidotiConference #SlimScan #GrowthStocks #CANSLIM